Daniele Donati is an internationally recognized Medicinal Chemist, with a solid scientific and managerial experience. He graduated in chemistry from the University of Pisa, Italy, and after a postgraduate experience at the same university, he started his experience in the pharmaceutical industry at Zambon SpA, Italy, taking care of process research for arylalkanoic acids. In 1986, Dr. Donati moved to GlaxoSmithKline, Italy (Glaxo at the time). After an initial experience in Chemical Development, he moved into Medicinal Chemistry Department where he took roles of growing responsibility; with the creation of GlaxoSmithKline (2000) he was appointed as Vice President, Medicinal Chemistry, Centre of Excellence for Drug Discovery in Psychiatry (Psychiatry CEDD) with responsibility over a group based in three different countries, Verona (Italy), Harlow (UK), and Zagreb (Croatia). Since 2008, Dr. Donati has been in charge of the Medicinal Chemistry Department at Nerviano Medical Sciences, Italy, a company specialized in oncology research. In the years, Dr. Donati has been involved in different therapeutic areas, such as cardiovascular, anti-infective, neurology, psychiatry, and oncology; main results are represented by the contribution given to the identification of more than 30 new chemical entities progressed into preclinical and clinical development. His scientific activity is certified by more than 130 publications as both author and coauthor (patents, peer-reviewed papers, posters, and oral communications) and by the memberships to a number of organizing committees for international and national symposia.
Biography Updated on 9 August 2012